Skip to main content

Table 1 Pretreatment patient characteristics and univariate associations with pathological complete remission

From: Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

 

All

pCR no

pCR yes

 
 

Mean or n

SD or %

Mean or n

SD or %

Mean or n

SD or %

P

Age

53.3

11.8

54.2

11.5

50.0

12.3

< 0.01

BMI

26.1

5.1

26.4

5.3

25.1

4.1

< 0.01

cT

       

   1

92

16.7

60

65.2

32

34.8

< 0.0001

   2

372

67.5

292

78.5

80

21.5

 

   3

26

4.7

24

92.3

2

7.7

 

   4

61

11.1

56

91.8

5

8.2

 

Grading

       

   1

28

5.6

26

92.9

2

7.1

< 0.00001

   2

301

60.1

269

89.4

32

10.6

 

   3

172

34.3

94

54.7

78

45.3

 

Histology

       

   Ductal

445

80.8

338

76.0

107

24.0

0.001

   Lobular

80

14.5

76

95.0

4

5.0

 

   Other

26

4.7

18

69.2

8

30.8

 

ER Status

       

   Negative

198

35.9

103

52.0

95

48.0

< 0.00001

   Positive

354

64.1

329

92.9

25

7.1

 

PR Status

       

   Negative

259

46.9

157

60.6

102

39.4

< 0.00001

   Positive

293

53.1

275

93.9

18

6.1

 

HER2 Status

       

   Negative

445

81.4

366

82.2

79

17.8

< 0.00001

   Positive

102

18.6

61

59.8

41

40.2

 

Ki67

       

   Low

162

29.3

155

95.7

7

4.3

< 0.00001

   High

390

70.7

277

71.0

113

29.0

 

Postoperative radiation

       

   No

63

15.9

47

74.6

16

25.4

0.94

   Yes

333

84.1

255

74.2

86

25.8

 
  1. BMI, body mass index; cT, clinical tumor stage (TNM classification); Ki67, proliferation status, with an immunohistological staining cut-off value of > 13%; pCR, pathological complete remission; ER, estrogen receptor; PR, progesterone receptor.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us